BIOGEN INC. - COMMON STOCK

Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis

07 2 2022 16:05:00 提供 Nasdaq GlobeNewswire

Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody

01 2 2022 07:30:00 提供 Nasdaq GlobeNewswire

Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors

31 1 2022 07:30:00 提供 Nasdaq GlobeNewswire

Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

27 1 2022 18:50:14 提供 Nasdaq GlobeNewswire

Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®

27 1 2022 07:30:00 提供 Nasdaq GlobeNewswire

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA

04 1 2022 07:34:32 提供 Nasdaq GlobeNewswire

Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review

22 12 2021 07:30:00 提供 Nasdaq GlobeNewswire

Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease

20 12 2021 07:00:00 提供 Nasdaq GlobeNewswire

Update on Regulatory Submission for Aducanumab in the European Union

17 12 2021 06:43:58 提供 Nasdaq GlobeNewswire

Update on the Phase 4 Confirmatory Study of ADUHELM®

16 12 2021 07:00:00 提供 Nasdaq GlobeNewswire